Sobi Reaps Benefits From Acquisitions, Commercial Focus
Revenues Grew By 56% In 2019
Sweden’s mid-sized pharmaceutical company, Swedish Orphan Biovitrum, has expanded into hematology and strengthened its immunology business, growing its top and bottom lines in 2019.
You may also be interested in...
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.
Swiss biotech Novimmune SA creates newco around Gamifant emapalumab and other immuno-oncology assets and then sells it to Sobi for CHF515m ($519.2m).
Swedish Orphan Biovitrum gains a boost to its US commercialization infrastructure, a product to make immunology a key part of its specialty care business, and financial flexibility to seek further product acquisitions, through an RSV products deal with AstraZeneca.